Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CEL-SCI CORPORATION

Delayed Nyse  -  04:00:00 2018-12-20 pm EST
2.740 USD   -0.36%
05/23Cel Sci Corp : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly Prolonged Overall Survival in Head and Neck Cancer-Phase 3 Data Presented at ESTRO 2023
AQ
05/15Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
BU
SummaryChartsNewsRatingsCalendarCompanyFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about CEL-SCI CORPORATION
05/16Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
AQ
05/15Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
BU
05/15CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikin..
CI
05/12Cel-sci : Fiscal Q2 Earnings Snapshot
AQ
05/12CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
BU
05/12CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
04/27CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of..
BU
04/20CEL-SCI to Pursue Canada's Conditional Approval Pathway for Multikine in the Treatment ..
AQ
04/19CEL-SCI to Pursue Canada's Conditional Approval Pathway for Multikine in the Treatment ..
BU
03/09CEL-SCI's Multikine Phase 3 Cancer Study Shows 43% Survival Extension
AQ
03/08CEL-SCI's Multikine Phase 3 Cancer Study Shows 43% Survival Extension
BU
03/08CEL-SCI Corporation Reports New Data from Its Pivotal Phase 3 Study
CI
03/06CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
AQ
03/03CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
BU
02/15CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
BU
More most relevant news
All news about CEL-SCI CORPORATION
05/23Cel Sci Corp : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
AQ
05/15Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
BU
05/15CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikin..
CI
05/12Cel-sci : Fiscal Q2 Earnings Snapshot
AQ
05/12CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
BU
05/12CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
05/02Cel Sci Corp : Other Events (form 8-K)
AQ
05/01Cel Sci Corp : Entry into a Material Definitive Agreement, Other Events, Financial Stateme..
AQ
04/27CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of..
BU
More news
News in other languages on CEL-SCI CORPORATION
05/15CEL-SCI Corporation annonce les derniers résultats de son étude pivot de phase 3 sur Mu..
05/12CEL-SCI Corporation annonce ses résultats pour le deuxième trimestre et le semestre clo..
03/08CEL-SCI Corporation présente de nouvelles données issues de son étude pivot de phase 3
02/14CEL-SCI Corporation annonce ses résultats pour le premier trimestre clos le 31 décembre..
2022CEL-SCI Corporation annonce ses résultats pour l'exercice complet clos le 30 septembre ..
2022L'auditeur de CEL-SCI Corporation met en doute la pérennité de l'entreprise.
2022Cel-Sci rapporte des données positives de l'étude de phase 3 sur le traitement néoadjuv..
2022Cel-Sci déclare que les résultats positifs de l'essai de phase 3 du médicament contre l..
2022CEL-SCI Corporation annonce les résultats de la phase 3 de Multikine« pour le cancer de..
2022CEL-SCI Corporation annonce ses résultats pour le troisième trimestre et les neuf mois ..
More news
Analyst Recommendations on CEL-SCI CORPORATION
2022EF Hutton Cuts Price Target on Cel-Sci to $16 From $17, Maintains Buy Rating
MT
2022EF Hutton Initiates Cel-Sci With Buy Rating, $17 Price Target
MT
2022EF Hutton Initiates Cel-Sci at Buy with $17 Price Target
MT
More recommendations
Press releases
05/23Cel Sci Corp : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
AQ
05/15Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly P..
BU
05/12Cel-sci : Fiscal Q2 Earnings Snapshot
AQ
05/12CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
BU
More press releases
Upcoming event on CEL-SCI CORPORATION
Stock markets for all
100% Free Registration
fermer